Portfolio
3
companies
Trademylux
Trademylux builds digital resale platforms for luxury goods and fine art.
Aveni
Aveni develops artificial intelligence platforms for speech analytics in business.
Aurum Biosciences
Aurum Biosciences develops novel oxygen carriers and diagnostic software for clinical use.
Jamie Andrew
Chair
Jamie brings extensive board and chair experience, notably with TRICAPITAL and Ranworth Capital. He also serves as a board observer for Gas Sensing Solutions.
LinkedIn
Moray Martin
CEO
Moray leads MB Martin and Partners as founder and CEO, alongside chairing TRICAPITAL Angels. His background includes directorships across solar investment and life sciences firms.
LinkedInTRICAPITAL and Scottish Enterprise backed the funding round to help launch the company's inaugural fine art resale marketplace.
"This is a project we have worked on for several years but was put on ice because of the Covid pandemic and we are now delighted to be supported financially and strategically by TRICAPITAL and Scottish Enterprise."
The TRICAPITAL-led round will fund team expansion and sector diversification for the Edinburgh fintech.
"In the new world, AI can be adopted throughout the customer journey, driving new insight, significant efficiency gains and better protecting the vulnerable. It’s a win-win situation. By using AI to help automate processes like quality assurance and risk monitoring, material cost reductions can be achieved. At the same time, companies gain targeted insights on customer experience and training opportunities for customer-facing staff."
The financing round was backed by Infinion Biopharma, the Scottish Investment Bank, Scottish Health Innovations, and TRICAPITAL.
"We are delighted to complete this second round with our initial investment partners and bringing in a new investment partner, Infinion. This funding will allow us to extend our work beyond the successfully completed pre-clinical trials where Aurum’s lead product has demonstrated great potential in both stroke treatment and diagnosis. We are especially pleased that Infinion have joined the investment and look forward to them helping to drive Aurum forward with their global expertise in the biopharma sector. There has been few new therapies or diagnostics approved for acute ischaemic stroke in recent years. Our products provide hope for the many patients, carers and healthcare professionals who live with the consequences of this devastating condition."
